Skip to content
Screener

NewAmsterdam Pharma Company NAMS Cash And Cash Equivalents At Carrying Value

Cash And Cash Equivalents At Carrying Value at other companies

Cal-Maine Foods logo
Cal-Maine FoodsCALM
$107.22M-78.5%
NewAmsterdam Pharma Company logo
NewAmsterdam Pharma CompanyNAMS
$424.15M-24.8%
SharkNinja logo
SharkNinjaSN
$779.83M—
TETRA Technologies logo
TETRA TechnologiesTTI
$154.58M+125%
Taboola.com Ltd. logo
Taboola.com Ltd.TBLA
$133.05M+15.5%
United Therapeutics logo
United TherapeuticsUTHR
$1.8B+13.2%

Other financials

Income statement

See full
Revenue$3.7M-80.7%
Operating income-$64.9M-82.0%
Net income-$64.1M-269%
EPS (diluted)-$0.52-247%

Balance sheet

See full
Cash & equivalents$424.2M-24.8%
Total debt$82.0K-75.0%
Total equity$631.4M-18.9%
Total assets$704.5M-13.6%

Cash flow

See full
Operating cash flow-$39.2M-4.1%
CapEx$80.0K-9.1%
Free cash flow-$39.3M-4.1%

Valuation

See full
Market cap$3.21B+20.9%
Enterprise value$2.78B+33.2%
P/S450.2×+409×

Profitability

See full
Operating margin-3,432.2%-3,753pp
Net margin-3,644.2%-3,946pp
FCF margin-2,018.3%-2,259pp

Returns & leverage

See full
Return on equity-36.8%+15.4pp
Debt / equity0×0.0×
Current ratio9×-12.1×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333824
Line itemJune 30,2026December 31,2025
(In thousands of USD)
Assets
Current assets:
Cash and cash equivalents424,151490,002
Prepayments and other receivables23,99638,138
Marketable securities, current209,703146,239
Restricted cash1,3571,321
Total current assets659,207675,700

Item 1. Financial Statements.

FAQ

What is NewAmsterdam Pharma Company's cash and cash equivalents at carrying value?
NewAmsterdam Pharma Company (NAMS) reported cash and cash equivalents at carrying value of $424.15M in Q2 2026.
How has NewAmsterdam Pharma Company's cash and cash equivalents at carrying value changed year-over-year?
NewAmsterdam Pharma Company's cash and cash equivalents at carrying value decreased by 24.8% year-over-year, from $563.86M to $424.15M.
What is the long-term trend for NewAmsterdam Pharma Company's cash and cash equivalents at carrying value?
Over 2 years (2023 to 2025), NewAmsterdam Pharma Company's cash and cash equivalents at carrying value has grown at a 20.0% compound annual growth rate (CAGR), from $340.45M to $490M.
What does cash and cash equivalents at carrying value mean?
Cash And Cash Equivalents At Carrying Value as reported by NewAmsterdam Pharma Company N.V. Ordinary Shares.

Ask your AI about NewAmsterdam Pharma Company's cash and cash equivalents at carrying value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude